-

Fulgent to Participate in Upcoming Conferences

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences:

  • UBS Global Healthcare Conference on Tuesday, November 12th at 2:45 PM Pacific Time
  • Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4th at 11:30 AM Eastern Time

Live webcasts of the sessions will be available on the Investor Relations section of the Fulgent website at ir.fulgentgenetics.com. Replay of the webcasts will be accessible at the same location beginning approximately one hour following the completion of the event.

About Fulgent

Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business, which was formerly referred to as the clinical diagnostic business, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.

Contacts

Investor Relations Contact:
The Blueshirt Group
Melanie Solomon, melanie@blueshirtgroup.com

Industry:

Fulgent Genetics, Inc.

NASDAQ:FLGT
Release Versions
English

Contacts

Investor Relations Contact:
The Blueshirt Group
Melanie Solomon, melanie@blueshirtgroup.com

More News From Fulgent Genetics, Inc.

Fulgent Reports First Quarter 2026 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2026. First Quarter 2026 Results: Revenue of $71.1 million GAAP loss of $24.8 million, or $(0.80) per share Non-GAAP loss of $11.0 million, or $(0.36) per share Adjusted EBITDA loss of $15.2 million Non-...

Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its abstract was selected to be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) rapid oral abstract session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in hall D1 of McCormick Place, Chicago. The abstra...

Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2026 financial results before the market opens on Friday, May 1, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer question...
Back to Newsroom